Back to top

crispr: Archive

Zacks Equity Research

Intellia (NTLA) Up on Positive Data Updates From HAE Study

Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema.

ADMAPositive Net Change NTLAPositive Net Change AKRONegative Net Change